| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare.
"After conducting a comprehensive review of our IP portfolio, we are confident that Spectral AI has effectively safeguarded its current and anticipated future product offerings through a combination of patents and trade secrets. During this review, we identified additional opportunities for the Company to enhance its position and add value for its shareholders by developing or acquiring IP applicable to the broader AI ecosystem—specifically within healthcare," said Pete Carlson, Chief Executive Officer. "We are fortunate to have one of the world's preeminent experts in IP monetization as our largest shareholder, Board member, and Chairman of our Executive Committee. He will collaborate closely with the Company on this initiative."
Spectral AI remains committed to advancing AI-driven solutions in healthcare, including opportunities and strategic developments fostered by its new subsidiary.
Posted In: MDAI
